| 0.028 -0.001 (-3.45%) | 06-17 15:55 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.03 | 1-year : | 0.04 |
| Resists | First : | 0.03 | Second : | 0.03 |
| Pivot price | 0.02  |
|||
| Supports | First : | 0.02 | Second : | 0.01 |
| MAs | MA(5) : | 0.02 |
MA(20) : | 0.02 |
| MA(100) : | 0.03 |
MA(250) : | 0.05 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.7 |
D(3) : | 47.9 |
| RSI | RSI(14): 57.5 |
|||
| 52-week | High : | 0.14 | Low : | 0.02 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GRTX ] has closed below upper band by 24.2%. Bollinger Bands are 30.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.03 - 0.03 | 0.03 - 0.03 |
| Low: | 0.03 - 0.03 | 0.03 - 0.03 |
| Close: | 0.03 - 0.03 | 0.03 - 0.03 |
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Tue, 31 Dec 2024
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Tue, 31 Dec 2024
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - GlobeNewswire
Thu, 15 Aug 2024
Galera Therapeutics Announces Plan of Liquidation and Dissolution Amid Financial Updates - MyChesCo
Wed, 14 Aug 2024
Galera Announces Board Approval of Complete Liquidation and Dissolution - GlobeNewswire
Thu, 08 Aug 2024
Galera Therapeutics settles lawsuit for $975,000 - Investing.com
Tue, 12 Oct 2021
Galera Appoints Mark J. Bachleda as Chief Commercial Officer - citybiz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 40 (M) |
| Held by Insiders | 36.2 (%) |
| Held by Institutions | 1 (%) |
| Shares Short | 2,120 (K) |
| Shares Short P.Month | 2,660 (K) |
| EPS | -0.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -48.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.46 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -0.06 |
| PEG Ratio | 0 |
| Price to Book value | -0.02 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.06 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|